Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy

Alfonso Quintás-Cardama, Sangbum Choi, Hagop Kantarjian, Elias Jabbour, Xuelin Huang, Jorge Cortes

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background Current recommendations for monitoring patients with chronic myeloid leukemia (CML) provide recommendations for response assessment and treatment only at 3, 6, 12, and 18 months. These recommendations are based on clinical trial outcomes computed from treatment start. Conditional survival estimates take into account the changing hazard rates as time from treatment elapses as a continuum. Patients and Methods We performed conditional survival analyses among patients with CML to improve prognostication at any time point during the course of therapy. We used 2 cohorts of patients with CML in chronic phase: 1 treated in the frontline DASISION (Dasatinib versus Imatinib Study in Treatment - Naïve CML) phase III study (n = 519) and another treated after imatinib treatment had failed in the dasatinib dose-optimization phase III CA180-034 study (n = 670). Conditional survival estimates were calculated. A modified Cox proportional hazards model was used to build a prognostic nomogram. Results As the time alive or free from events from commencement of treatment increased, conditional survival estimates changed. No differences were observed regarding future outcomes between patients treated with imatinib or dasatinib in the frontline setting for patients with the same breakpoint cluster region-abelson 1 (BCR-ABL1) transcript levels evaluated at the same time point. Age older than 60 years greatly affected future outcomes particularly in the short-term. Conditional survival-based nomograms allowed the prediction of future outcomes at any time point. Conclusion In summary, we designed a calculator to predict future outcomes of patients with CML at any time point during the course of therapy.

Original languageEnglish
Pages (from-to)327-334.e8
JournalClinical Lymphoma, Myeloma and Leukemia
Volume14
Issue number4
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Leukemia, Myeloid, Chronic Phase
Nomograms
Survival
Therapeutics
Physiologic Monitoring
Survival Analysis
Proportional Hazards Models
Clinical Trials
Imatinib Mesylate
Dasatinib

Keywords

  • BCR-ABL1
  • CML
  • Conditional survival
  • Nomogram
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. / Quintás-Cardama, Alfonso; Choi, Sangbum; Kantarjian, Hagop; Jabbour, Elias; Huang, Xuelin; Cortes, Jorge.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, No. 4, 01.01.2014, p. 327-334.e8.

Research output: Contribution to journalArticle

Quintás-Cardama, Alfonso ; Choi, Sangbum ; Kantarjian, Hagop ; Jabbour, Elias ; Huang, Xuelin ; Cortes, Jorge. / Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. In: Clinical Lymphoma, Myeloma and Leukemia. 2014 ; Vol. 14, No. 4. pp. 327-334.e8.
@article{0c27f67a767b49bebf45878510b220b2,
title = "Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy",
abstract = "Background Current recommendations for monitoring patients with chronic myeloid leukemia (CML) provide recommendations for response assessment and treatment only at 3, 6, 12, and 18 months. These recommendations are based on clinical trial outcomes computed from treatment start. Conditional survival estimates take into account the changing hazard rates as time from treatment elapses as a continuum. Patients and Methods We performed conditional survival analyses among patients with CML to improve prognostication at any time point during the course of therapy. We used 2 cohorts of patients with CML in chronic phase: 1 treated in the frontline DASISION (Dasatinib versus Imatinib Study in Treatment - Na{\"i}ve CML) phase III study (n = 519) and another treated after imatinib treatment had failed in the dasatinib dose-optimization phase III CA180-034 study (n = 670). Conditional survival estimates were calculated. A modified Cox proportional hazards model was used to build a prognostic nomogram. Results As the time alive or free from events from commencement of treatment increased, conditional survival estimates changed. No differences were observed regarding future outcomes between patients treated with imatinib or dasatinib in the frontline setting for patients with the same breakpoint cluster region-abelson 1 (BCR-ABL1) transcript levels evaluated at the same time point. Age older than 60 years greatly affected future outcomes particularly in the short-term. Conditional survival-based nomograms allowed the prediction of future outcomes at any time point. Conclusion In summary, we designed a calculator to predict future outcomes of patients with CML at any time point during the course of therapy.",
keywords = "BCR-ABL1, CML, Conditional survival, Nomogram, Prognosis",
author = "Alfonso Quint{\'a}s-Cardama and Sangbum Choi and Hagop Kantarjian and Elias Jabbour and Xuelin Huang and Jorge Cortes",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.clml.2014.01.003",
language = "English",
volume = "14",
pages = "327--334.e8",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy

AU - Quintás-Cardama, Alfonso

AU - Choi, Sangbum

AU - Kantarjian, Hagop

AU - Jabbour, Elias

AU - Huang, Xuelin

AU - Cortes, Jorge

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background Current recommendations for monitoring patients with chronic myeloid leukemia (CML) provide recommendations for response assessment and treatment only at 3, 6, 12, and 18 months. These recommendations are based on clinical trial outcomes computed from treatment start. Conditional survival estimates take into account the changing hazard rates as time from treatment elapses as a continuum. Patients and Methods We performed conditional survival analyses among patients with CML to improve prognostication at any time point during the course of therapy. We used 2 cohorts of patients with CML in chronic phase: 1 treated in the frontline DASISION (Dasatinib versus Imatinib Study in Treatment - Naïve CML) phase III study (n = 519) and another treated after imatinib treatment had failed in the dasatinib dose-optimization phase III CA180-034 study (n = 670). Conditional survival estimates were calculated. A modified Cox proportional hazards model was used to build a prognostic nomogram. Results As the time alive or free from events from commencement of treatment increased, conditional survival estimates changed. No differences were observed regarding future outcomes between patients treated with imatinib or dasatinib in the frontline setting for patients with the same breakpoint cluster region-abelson 1 (BCR-ABL1) transcript levels evaluated at the same time point. Age older than 60 years greatly affected future outcomes particularly in the short-term. Conditional survival-based nomograms allowed the prediction of future outcomes at any time point. Conclusion In summary, we designed a calculator to predict future outcomes of patients with CML at any time point during the course of therapy.

AB - Background Current recommendations for monitoring patients with chronic myeloid leukemia (CML) provide recommendations for response assessment and treatment only at 3, 6, 12, and 18 months. These recommendations are based on clinical trial outcomes computed from treatment start. Conditional survival estimates take into account the changing hazard rates as time from treatment elapses as a continuum. Patients and Methods We performed conditional survival analyses among patients with CML to improve prognostication at any time point during the course of therapy. We used 2 cohorts of patients with CML in chronic phase: 1 treated in the frontline DASISION (Dasatinib versus Imatinib Study in Treatment - Naïve CML) phase III study (n = 519) and another treated after imatinib treatment had failed in the dasatinib dose-optimization phase III CA180-034 study (n = 670). Conditional survival estimates were calculated. A modified Cox proportional hazards model was used to build a prognostic nomogram. Results As the time alive or free from events from commencement of treatment increased, conditional survival estimates changed. No differences were observed regarding future outcomes between patients treated with imatinib or dasatinib in the frontline setting for patients with the same breakpoint cluster region-abelson 1 (BCR-ABL1) transcript levels evaluated at the same time point. Age older than 60 years greatly affected future outcomes particularly in the short-term. Conditional survival-based nomograms allowed the prediction of future outcomes at any time point. Conclusion In summary, we designed a calculator to predict future outcomes of patients with CML at any time point during the course of therapy.

KW - BCR-ABL1

KW - CML

KW - Conditional survival

KW - Nomogram

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84904621638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904621638&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2014.01.003

DO - 10.1016/j.clml.2014.01.003

M3 - Article

C2 - 24594142

AN - SCOPUS:84904621638

VL - 14

SP - 327-334.e8

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 4

ER -